{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:35:19Z","timestamp":1793223319720,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007363","name":"Fondazione Citt\u00e0 della Speranza","doi-asserted-by":"publisher","award":["IRP-synergy grant"],"award-info":[{"award-number":["IRP-synergy grant"]}],"id":[{"id":"10.13039\/100007363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007363","name":"Fondazione Citt\u00e0 della Speranza","doi-asserted-by":"publisher","award":["IRP-synergy"],"award-info":[{"award-number":["IRP-synergy"]}],"id":[{"id":"10.13039\/100007363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-20562"],"award-info":[{"award-number":["IG-20562"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR CN3-National Center for Gene Therapy and Drugs Based on RNA Technology"],"award-info":[{"award-number":["PNRR CN3-National Center for Gene Therapy and Drugs Based on RNA Technology"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR CN3-National Center for Gene Therapy and Drugs Based on RNA Technology"],"award-info":[{"award-number":["PNRR CN3-National Center for Gene Therapy and Drugs Based on RNA Technology"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Altheia science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72361-4","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:43:40Z","timestamp":1778201020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-5263","authenticated-orcid":false,"given":"Martina","family":"Pigazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Da Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0196-3445","authenticated-orcid":false,"given":"Olivia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-5638","authenticated-orcid":false,"given":"Giovanni","family":"Faggin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Mattera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8141-7305","authenticated-orcid":false,"given":"Paolo","family":"Rizzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-4423","authenticated-orcid":false,"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-9302","authenticated-orcid":false,"given":"Giuseppe","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-0870","authenticated-orcid":false,"given":"Alessandra","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"72361_CR1","doi-asserted-by":"publisher","first-page":"04045","DOI":"10.7189\/jogh.14.04045","volume":"14","author":"Y Cui","year":"2024","unstructured":"Cui, Y. & Yan, Y. The global burden of childhood and adolescent leukaemia and attributable risk factors: an analysis of the Global Burden of Disease Study 2019. J. Glob. Health 14, 04045 (2024).","journal-title":"J. Glob. Health"},{"key":"72361_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11, 41 (2021).","journal-title":"Blood Cancer J."},{"key":"72361_CR3","doi-asserted-by":"publisher","unstructured":"Locatelli, F. et al. Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013. J. Hematol. Oncol. https:\/\/doi.org\/10.1186\/s13045-026-01798-3 (2026). Epub ahead of print.","DOI":"10.1186\/s13045-026-01798-3"},{"key":"72361_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021011694","volume":"138","author":"JE Rubnitz","year":"2021","unstructured":"Rubnitz, J. E. & Kaspers, G. J. L. How I treat pediatric acute myeloid leukemia. Blood 138, 1009\u20131018 (2021).","journal-title":"Blood"},{"key":"72361_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cancers16010078","volume":"16","author":"V Ceolin","year":"2023","unstructured":"Ceolin, V. et al. The PedAL\/EuPAL Project: a global initiative to address the unmet medical needs of pediatric patients with relapsed or refractory acute myeloid leukemia. Cancers 16, 78 (2023).","journal-title":"Cancers"},{"key":"72361_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/jcm4010127","volume":"4","author":"J De Rooij","year":"2015","unstructured":"De Rooij, J., Zwaan, C. & Van den Heuvel-Eibrink, M. Pediatric AML: from biology to clinical management. J. Clin. Med. 4, 127\u2013149 (2015).","journal-title":"J. Clin. Med."},{"key":"72361_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2018.05.009","volume":"369","author":"F Arabi","year":"2018","unstructured":"Arabi, F., Torabi-Rahvar, M., Shariati, A., Ahmadbeigi, N. & Naderi, M. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Exp. Cell Res. 369, 1\u201310 (2018).","journal-title":"Exp. Cell Res."},{"key":"72361_CR8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarf\u00f2","year":"2018","unstructured":"Scarf\u00f2, I. et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132, 1495\u20131506 (2018).","journal-title":"Blood"},{"key":"72361_CR9","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","volume":"36","author":"E Jacoby","year":"2022","unstructured":"Jacoby, E. et al. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia 36, 1525\u20131532 (2022).","journal-title":"Leukemia"},{"key":"72361_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz, L. M. et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J. Clin. Oncol. 40, 945\u2013955 (2022).","journal-title":"J. Clin. Oncol."},{"key":"72361_CR11","doi-asserted-by":"publisher","first-page":"e27214","DOI":"10.4161\/onci.27214","volume":"2","author":"A Mardiros","year":"2013","unstructured":"Mardiros, A., Brown, C. E., Budde, L. E., Wang, X. & Forman, S. J. Acute myeloid leukemia therapeutics. Oncoimmunology 2, e27214 (2013).","journal-title":"Oncoimmunology"},{"key":"72361_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/cancers14051241","volume":"14","author":"P Vishwasrao","year":"2022","unstructured":"Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L. & Hui, S. K. Emerging CAR T cell strategies for the treatment of AML. Cancers 14, 1241 (2022).","journal-title":"Cancers"},{"key":"72361_CR13","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan, C. M. et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J. Clin. Oncol. 33, 2949\u20132962 (2015).","journal-title":"J. Clin. Oncol."},{"key":"72361_CR14","doi-asserted-by":"crossref","unstructured":"Kavanagh, S. et al. Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight 2, e95679 (2017).","DOI":"10.1172\/jci.insight.95679"},{"key":"72361_CR15","doi-asserted-by":"crossref","unstructured":"Epperly, R., Gottschalk, S. & Velasquez, M. P. A bump in the road: how the hostile AML microenvironment affects CAR T Cell Therapy. Front. Oncol. 10, 262 (2020).","DOI":"10.3389\/fonc.2020.00262"},{"key":"72361_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ccr.2014.03.002","volume":"25","author":"J Duque-Afonso","year":"2014","unstructured":"Duque-Afonso, J. & Cleary, M. L. The AML Salad Bowl. Cancer Cell 25, 265\u2013267 (2014).","journal-title":"Cancer Cell"},{"key":"72361_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72361_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher, J. C. et al. Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol. Ther. Oncolytics 31, 100751 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"72361_CR19","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"72361_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/17474086.2024.2420614","volume":"17","author":"CK Colonne","year":"2024","unstructured":"Colonne, C. K., Kimble, E. L. & Turtle, C. J. Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia. Expert Rev. Hematol. 17, 797\u2013818 (2024).","journal-title":"Expert Rev. Hematol."},{"key":"72361_CR21","doi-asserted-by":"crossref","unstructured":"Kheirkhah, A. H. et al. Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia. Front. Immunol. 15, 1460437 (2024).","DOI":"10.3389\/fimmu.2024.1460437"},{"key":"72361_CR22","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer, C. et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol. Ther. 28, 2237\u20132251 (2020).","journal-title":"Mol. Ther."},{"key":"72361_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"72361_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer, T. et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138, 318\u2013330 (2021).","journal-title":"Blood"},{"key":"72361_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige, Y. et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7, 708\u2013717 (2010).","journal-title":"Cell Stem Cell"},{"key":"72361_CR26","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter, R. B., Appelbaum, F. R., Estey, E. H. & Bernstein, I. D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198\u20136208 (2012).","journal-title":"Blood"},{"key":"72361_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1182\/blood.2023023210","volume":"145","author":"HJ Silva","year":"2025","unstructured":"Silva, H. J. et al. CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML. Blood 145, 720\u2013731 (2025).","journal-title":"Blood"},{"key":"72361_CR28","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu, P. et al. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood 145, 1022\u20131033 (2025).","journal-title":"Blood"},{"key":"72361_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood-2022-170300","volume":"140","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. CD84 is a therapeutically targetable driver of leukemogenesis via disruption of energy supply in acute myeloid leukemia. Blood 140, 89\u201390 (2022).","journal-title":"Blood"},{"key":"72361_CR30","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1182\/blood-2022-165339","volume":"140","author":"L P\u00e9rez-Amill","year":"2022","unstructured":"P\u00e9rez-Amill, L. et al. CD84: a novel target for CAR T-Cell Therapy for acute myeloid leukemia. Blood 140, 7379\u20137381 (2022).","journal-title":"Blood"},{"key":"72361_CR31","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/leu.2016.98","volume":"30","author":"C Tregnago","year":"2016","unstructured":"Tregnago, C. et al. CREB engages C\/EBP\u03b4 to initiate leukemogenesis. Leukemia 30, 1887\u20131896 (2016).","journal-title":"Leukemia"},{"key":"72361_CR32","doi-asserted-by":"publisher","first-page":"D1138","DOI":"10.1093\/nar\/gkad993","volume":"52","author":"MH G\u00edslason","year":"2024","unstructured":"G\u00edslason, M. H. et al. BloodSpot 3.0: a database of gene and protein expression data in normal and malignant haematopoiesis. Nucleic Acids Res. 52, D1138\u2013D1142 (2024).","journal-title":"Nucleic Acids Res."},{"key":"72361_CR33","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1182\/blood-2024-204084","volume":"144","author":"Macarena Oporto Espuelas","year":"2024","unstructured":"Oporto Espuelas, M. acarena et al. Single cell multimodal framework identifies CD84 as a leukaemic stem cell target in paediatric AML. Blood 144, 4317 (2024).","journal-title":"Blood"},{"key":"72361_CR34","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2023-180387","volume":"142","author":"Xiaomei Zhang","year":"2023","unstructured":"Zhang, X. iaomei et al. A phase I clinical trial of CLL-1 CAR-T cells for the treatment of relapsed\/refractory acute myeloid leukemia in adults. Blood 142, 2106 (2023).","journal-title":"Blood"},{"key":"72361_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03797-7","volume":"20","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML). J. Transl. Med. 20, 600 (2022).","journal-title":"J. Transl. Med."},{"key":"72361_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso, S. et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J. Hematol. Oncol. 15, 163 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"72361_CR37","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.beha.2020.101224","volume":"33","author":"MC Clark","year":"2020","unstructured":"Clark, M. C. & Stein, A. CD33 directed bispecific antibodies in acute myeloid leukemia. Best. Pract. Res. Clin. Haematol. 33, 101224 (2020).","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"72361_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy, G. L. et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood 137, 751\u2013762 (2021).","journal-title":"Blood"},{"key":"72361_CR39","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1182\/blood-2024-206204","volume":"144","author":"Melia Blankenfeld","year":"2024","unstructured":"Blankenfeld, M. elia et al. Effective dual targeting of PRAME and WT1 with CD33-gated ARTEMIS\u00ae antibody-TCR platform in acute myeloid leukemia. Blood 144, 3417 (2024).","journal-title":"Blood"},{"key":"72361_CR40","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood.2020010477","volume":"138","author":"C Augsberger","year":"2021","unstructured":"Augsberger, C. et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood 138, 2655\u20132669 (2021).","journal-title":"Blood"},{"key":"72361_CR41","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1182\/blood-2024-206777","volume":"144","author":"R Zhang","year":"2024","unstructured":"Zhang, R., Wang, Y., Zhao, Y., Zhao, M., Subklewe, M. & Zhao, M. Split CAR-T cells targeting CD312 and TIM-3 for AML to reduce the risk of antigen escape. Blood 144, 4795 (2024).","journal-title":"Blood"},{"key":"72361_CR42","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1182\/blood-2024-212075","volume":"144","author":"DanielleC Kirkey","year":"2024","unstructured":"Kirkey, D. anielleC. et al. Potent target-specific efficacy of CAR T cells directed toward the AML and KMT2A-rearranged specific antigen CLEC2A. Blood 144, 2050 (2024).","journal-title":"Blood"},{"key":"72361_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05705-7","volume":"22","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia. J. Transl. Med. 22, 888 (2024).","journal-title":"J. Transl. Med."},{"key":"72361_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte, T. et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat. Commun. 15, 8439 (2024).","journal-title":"Nat. Commun."},{"key":"72361_CR45","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36, 2596\u20132604 (2022).","journal-title":"Leukemia"},{"key":"72361_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 24, 103\u2013112 (2018).","journal-title":"Nat. Med."},{"key":"72361_CR47","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3390\/cancers15102713","volume":"15","author":"E Atilla","year":"2023","unstructured":"Atilla, E. & Benabdellah, K. The Black Hole: CAR T Cell Therapy in AML. Cancers 15, 2713 (2023).","journal-title":"Cancers"},{"key":"72361_CR48","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/onc.2016.238","volume":"36","author":"A Marom","year":"2017","unstructured":"Marom, A. et al. CD84 mediates CLL-microenvironment interactions. Oncogene 36, 628\u2013638 (2017).","journal-title":"Oncogene"},{"key":"72361_CR49","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3324\/haematol.2023.283817","volume":"109","author":"S Naik","year":"2024","unstructured":"Naik, S., Velasquez, M. P. & Gottschalk, S. Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: How far are we from a clinical application? Haematologica 109, 1656\u20131667 (2024).","journal-title":"Haematologica"},{"key":"72361_CR50","doi-asserted-by":"publisher","unstructured":"Tharakan, S., Tremblay, D. & Azzi, J. Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies. Leuk. Lymphoma 1\u201314. https:\/\/doi.org\/10.1080\/10428194.2024.2414112 (2024).","DOI":"10.1080\/10428194.2024.2414112"},{"key":"72361_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","volume":"42","author":"E Peroni","year":"2023","unstructured":"Peroni, E., Randi, M. L., Rosato, A. & Cagnin, S. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. J. Exp. Clin. Cancer Res. 42, 259 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"72361_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2018.10.017","volume":"204","author":"M Cuenca","year":"2019","unstructured":"Cuenca, M., Sintes, J., L\u00e1nyi, \u00c1 & Engel, P. CD84 cell surface signaling molecule: an emerging biomarker and target for cancer and autoimmune disorders. Clin. Immunol. 204, 43\u201349 (2019).","journal-title":"Clin. Immunol."},{"key":"72361_CR53","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2023-184362","volume":"142","author":"M Gunes","year":"2023","unstructured":"Gunes, M., Rosen, S. T. & Gunes, E. G. CD84 (SLAMF5) as a potential target for immunomodulation in cutaneous T-cell lymphoma (CTCL). Blood 142, 4393\u20134393 (2023).","journal-title":"Blood"},{"key":"72361_CR54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.14523","volume":"177","author":"B Buldini","year":"2017","unstructured":"Buldini, B. et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol. Br. J. Haematol. 177, 116\u2013126 (2017).","journal-title":"Br. J. Haematol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72361-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:01:32Z","timestamp":1784113292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72361"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72361-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.B. and M.P. are inventors on the following patent applications: PCT\/EP2022\/059031 and PCT\/EP2023\/059054. Alhena Science owns the rights to its exploitation. P.R. is an employee of Alhena Science. A.B. and M.P. are scientific advisors for Alhena Science; A.B. and M.P. are shareholders of the company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6205"}}